Ara-C is named as an intervention in 12 current clinical trials in our China, USA, UK and India registers. 7 are recruiting patients now. The most common phase is Phase 2. The sponsor with the most trials is The First Affiliated Hospital of Soochow University (2). The most-studied condition is Acute Myeloid Leukemia.
| Study | Phase | Status | Lead sponsor | Registers |
|---|---|---|---|---|
|
Studies to Assess Ziftomenib in Combination With Ven+Aza or 7+3 in Patients With Untreated NPM1-m or KMT2A-r AML
NCT07007312 · ClinicalTrials.gov ↗ · Acute Myeloid Leukemia (AML)
|
Phase 3 | Recruiting | Kura Oncology, Inc. | UK, USA |
|
Efficacy and Safety of Low-dose Chemotherapy Plus Immuno-targeted Drugs in Newly Diagnosed Adult Ph- B-ALL
NCT06387121 · ClinicalTrials.gov ↗ · Precursor Cell Lymphoblastic Leukemia-Lymphoma
|
Phase 2 | Recruiting | Institute of Hematology & Blood Diseases Hospital, China | China |
|
Linperlisib Combined With Immunochemotherapy in Relapsed/Refractory LBCL
NCT06489808 · ClinicalTrials.gov ↗ · Relapsed/Refractory Large B-Cell Lymphoma
|
Phase 2 | Recruiting | Institute of Hematology & Blood Diseases Hospital, China | China |
|
Blinatumomab Plus Venetoclax Sequenced With Inotuzumab Ozogamicin in Treating B-ALL
NCT06554626 · ClinicalTrials.gov ↗ · Precursor B-Cell Lymphoblastic Leukemia
|
Phase 2 | Recruiting | First Affiliated Hospital of Zhejiang University | China |
|
VHAG in Treating R/R T-ALL/LBL
NCT06742463 · ClinicalTrials.gov ↗ · Acute T Lymphpblastic Leukemia/Lymphoma
|
Phase 2 | Recruiting | First Affiliated Hospital of Zhejiang University | China |
|
Venetoclax-containing Therapy Combined With Microtransplant for Newly Diagnosed AML
NCT07078591 · ClinicalTrials.gov ↗ · Acute Myeloid Leukemia
|
Phase 2 | Recruiting | Beijing 302 Hospital | China |
|
Efficacy and Safety of Low-Dose Cytarabine Combined With Thalidomide in Adult Patients With Untreated LCH
NCT07187193 · ClinicalTrials.gov ↗ · Langerhans Cell Histiocytosis
|
Phase 2 | Recruiting | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | China |
|
CLAG+VEN vs CLAG in the Treatment of Relapsed/Refractory AML
NCT06763666 · ClinicalTrials.gov ↗ · Relapsed/Refractory AML
|
Phase 4 | Not yet open | Nanfang Hospital, Southern Medical University | China |
|
A Study of VABu Conditioning Regimen in Allo-HSCT for AML Patients
NCT07762508 · ClinicalTrials.gov ↗ · Leukemia, Myeloid, Acute(AML), Hematopoietic Stem Cell Transplantation (HSCT)
|
Not applicable | Not yet open | The First Affiliated Hospital of Soochow University | China |
|
Galinpepimut-S Versus Investigator's Choice of Best Available Therapy for Maintenance in AML CR2/CRp2
NCT04229979 · Acute Myeloid Leukemia
|
Phase 3 | Active, closed | Sellas Life Sciences Group | USA, India |
|
Venetoclax + Decitabine vs. "7+3" Induction Chemotherapy in Young AML
NCT05177731 · ClinicalTrials.gov ↗ · AML, Adult, Chemotherapy Effect
|
Phase 3 | Active, closed | Chen Suning | China |
|
Study of A Venetoclax-based, Anthracycline-free Regimen in Newly Diagnosed CBFฮฒ::MYH11(+) AML
NCT06429098 · ClinicalTrials.gov ↗ · Acute Myeloid Leukemia
|
Phase 2 | Active, closed | The First Affiliated Hospital of Soochow University | China |
Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
| Lead sponsor | Trials |
|---|---|
| The First Affiliated Hospital of Soochow University | 2 |
| First Affiliated Hospital of Zhejiang University | 2 |
| Institute of Hematology & Blood Diseases Hospital, China | 2 |
| Kura Oncology, Inc. | 1 |
| Sellas Life Sciences Group | 1 |
| Chen Suning | 1 |
| Beijing 302 Hospital | 1 |
| Nanfang Hospital, Southern Medical University | 1 |
| Cancer Institute and Hospital, Chinese Academy of Medical Sciences | 1 |
| Register | Trials | Recruiting |
|---|---|---|
| Clinical trials in China | 10 | 6 |
| Clinical trials in USA | 2 | 1 |
| Clinical trials in UK | 1 | 1 |
| Clinical trials in India | 1 | 0 |
A trial with sites in more than one country appears in each of those registers.
12 current trials in our China, USA, UK and India registers name Ara-C as a drug or biological intervention, as of the registry sync on 26 September 2026. Completed and withdrawn studies are not counted.
Yes. 7 of the 12 trials are recruiting: 6 with sites in China, 1 with sites in USA and 1 with sites in UK. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.
The First Affiliated Hospital of Soochow University (2), First Affiliated Hospital of Zhejiang University (2), Institute of Hematology & Blood Diseases Hospital, China (2) and Kura Oncology, Inc (1), among 9 lead sponsors in total. The number in brackets is how many trials each organisation leads.
Every trial, status, phase and sponsor on this page is copied from public ClinicalTrials.gov records by a daily sync. Nothing here describes how Ara-C works or whether it is effective, and it is not medical advice.
Everything on this page is copied from public ClinicalTrials.gov registry records โ it is not written from memory, and nothing here describes how Ara-C works or whether it is effective. Each trial links to its own record so you can check it yourself.
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists Ara-C (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 26 Sep 2026.